In the past week, XFOR stock has gone down by -7.07%, with a monthly gain of 9.20% and a quarterly plunge of -61.49%. The volatility ratio for the week is 10.27%, and the volatility levels for the last 30 days are 7.25% for X4 Pharmaceuticals Inc The simple moving average for the last 20 days is 7.59% for XFOR stock, with a simple moving average of -71.99% for the last 200 days.
Is It Worth Investing in X4 Pharmaceuticals Inc (NASDAQ: XFOR) Right Now?
X4 Pharmaceuticals Inc (NASDAQ: XFOR) has a price-to-earnings ratio of 1.64x that is above its average ratio. Additionally, the 36-month beta value for XFOR is 0.67. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for XFOR is 3.86M and currently, short sellers hold a 8.09% ratio of that float. The average trading volume of XFOR on June 10, 2025 was 130.48K shares.
XFOR) stock’s latest price update
The stock of X4 Pharmaceuticals Inc (NASDAQ: XFOR) has decreased by -11.11 when compared to last closing price of 4.14. Despite this, the company has experienced a -7.07% fall in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-10 that BOSTON, June 10, 2025 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to mavorixafor, an oral CXCR4 antagonist, for the treatment of chronic neutropenia (CN). The company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in certain primary CN conditions.
Analysts’ Opinion of XFOR
Many brokerage firms have already submitted their reports for XFOR stocks, with B. Riley Securities repeating the rating for XFOR by listing it as a “Neutral.” The predicted price for XFOR in the upcoming period, according to B. Riley Securities is $1 based on the research report published on December 12, 2023 of the previous year 2023.
B. Riley Securities, on the other hand, stated in their research note that they expect to see XFOR reach a price target of $3. The rating they have provided for XFOR stocks is “Buy” according to the report published on August 30th, 2023.
Cantor Fitzgerald gave a rating of “Overweight” to XFOR, setting the target price at $3 in the report published on December 22nd of the previous year.
XFOR Trading at -19.43% from the 50-Day Moving Average
After a stumble in the market that brought XFOR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.14% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at XFOR starting from Baldry Mark, who purchase 1,032 shares at the price of $2.48 back on May 16 ’25. After this action, Baldry Mark now owns 25,337 shares of X4 Pharmaceuticals Inc, valued at $2,561 using the latest closing price.
Baldry Mark, the Chief Commercial Officer of X4 Pharmaceuticals Inc, purchase 13,404 shares at $0.34 during a trade that took place back on Nov 15 ’24, which means that Baldry Mark is holding 129,173 shares at $4,598 based on the most recent closing price.
Stock Fundamentals for XFOR
Current profitability levels for the company are sitting at:
- -0.27 for the present operating margin
- 0.82 for the gross margin
The net margin for X4 Pharmaceuticals Inc stands at 0.47. The total capital return value is set at -0.08. Equity return is now at value 121.75, with 12.05 for asset returns.
Based on X4 Pharmaceuticals Inc (XFOR), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -45.47. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -1.24.
Currently, EBITDA for the company is -27.58 million with net debt to EBITDA at 0.37. When we switch over and look at the enterprise to sales, we see a ratio of -0.53. The receivables turnover for the company is 26.72for trailing twelve months and the total asset turnover is 0.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.70.
Conclusion
In conclusion, X4 Pharmaceuticals Inc (XFOR) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
